Rezolute's 2026 FDA meeting and trial results could redefine its future

Rezolute is nearing significant milestones in 2026, with a crucial FDA meeting in early 2026 to discuss its congenital hyperinsulinism (cHI) treatment program. Investors are closely monitoring the biopharma company as it prepares for key data releases later in the year.

The company's market capitalization is approximately 285.60 million EUR, with shares trading between $3.28 and $3.65 (around 2.86-2.90 EUR). Recent gains of +19.28% over seven days and +34.69% over 30 days indicate growing stock market interest as of February 2026.

Rezolute's latest financial report, covering Q2 fiscal 2026 (ended December 31, 2025), shows ongoing net losses but highlights a strong cash position. The firm held $132.9 million in cash and equivalents at the end of 2025, providing a buffer ahead of key trials. Research and development spending for the quarter reached $14.3 million, underscoring its focus on clinical progress.

The upLIFT Phase 3 trial has become the company's central priority. This study evaluates ersodetug for tumour-induced hyperinsulinism (tHI), with topline results expected in the second half of 2026. A positive outcome could significantly boost Rezolute's stock market valuation and shape its future direction.

The upcoming FDA meeting in early 2026 will determine the regulatory path for its cHI treatment. Depending on the feedback, Rezolute may advance its current program or need to reallocate resources entirely. Investors are now assessing how well management deploys its capital before these high-stakes data readouts.

Rezolute's next steps hinge on two critical events: the FDA discussion in early 2026 and the upLIFT trial results due later in the year. The company's cash reserves and recent stock market performance suggest cautious optimism, but operational execution will determine its trajectory. Success in these areas could redefine its market position and financial outlook.